Nat Med | 2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA
PubMed
PMID: 38195751
Abstract
Related Articles
CIBMTR Study #: CIBMTR_NA